LOVENOX (PRESERVATIVE FREE)

LOE Approaching

enoxaparin sodium

Sanofi
NDASUBCUTANEOUSINJECTABLEPriority Review
Approved
Mar 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3

Mechanism of Action

properties.

Indications (6)

deep vein thrombosis (DVT)which may lead to pulmonary embolism (PE): in patients undergoing abdominal surgeryduringfollowing hospitalization in patients undergoing knee replacement surgery in medical patientsnon–Q-wave myocardial infarctionconcurrently administered with aspirin

Clinical Trials (3)

NCT00916669Phase 2Withdrawn

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

Started Jul 2008
0
Small Cell Lung Cancer
NCT00349180Phase 3Completed

Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

Started Jun 2006
156 enrolled
Arthroplasty, Replacement, Hip
NCT00232271Phase 4Terminated

The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Started Aug 2005
35 enrolled
Deep Vein Thrombosis
Company
Sanofi
Sanofi
PARIS, France
1166 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers